Prosecution Insights
Last updated: April 19, 2026

Examiner: PEEBLES, KATHERINE

Tech Center 1600 • Art Units: 1617

This examiner grants 36% of resolved cases

Performance Statistics

36.3%
Allow Rate
-23.7% vs TC avg
558
Total Applications
+49.5%
Interview Lift
1145
Avg Prosecution Days
Based on 485 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
8.1%
§102 Novelty
41.4%
§103 Obviousness
26.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18274964 POLYMERIC MICROPARTICLES, COMPOSITIONS, AND METHODS FOR SUSTAINED RELEASE OF AN ACTIVE AGENT SUSCEPTIBLE TO ABUSE Non-Final OA Ohio State Innovation Foundation
15962327 COMPOSITIONS WITH ANIONIC AND CATIONIC POLYMERS HAVING IMPROVED BENEFITS Non-Final OA The Procter & Gamble Company
18464127 SURFACE COATING PPSU NANOPARTICLES FOR THERAPEUTIC MODULATION OF MAST CELLS Non-Final OA Northwestern University
17346615 STABLE IODINE-CONTAINING ANTIMICROBIAL TEAT DIP COMPOSITIONS Final Rejection ECOLAB USA INC.
18248139 IRON OXIDE NANOPARTICLE FOR SUPPRESSING DRUG-RESISTANT GENE FOR THE TREATMENT OF GLIOBLASTOMA Non-Final OA University of Washington
19171664 FERTILIZER COMPOSITION CONTAINING A CARBON-BASED ADDITIVE AND METHODS OF MAKING SAME Final Rejection The Mosaic Company
18652169 PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS Non-Final OA L'OREAL
18478091 NAIL POLISH COMPOSITION CONTAINING PIPERIDINOL COMPOUND Non-Final OA L'OREAL
19065403 PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAM Final Rejection SLAYBACK PHARMA LLC
18705455 SPRAY-DRIED COMPOSITIONS AND METHODS OF PREPARATION Non-Final OA NATIONAL UNIVERSITY OF SINGAPORE
18035174 THERAPEUTIC, RADIOLABELED NANOPARTICLES AND METHODS OF USE THEREOF Final Rejection The General Hospital Corporation
17862857 AGROCHEMICAL GEL COMPOSITIONS Final Rejection MONSANTO TECHNOLOGY LLC
18557650 USE OF PERILLYL ALCOHOL TO ENHANCE LEVO-DOPA DELIVERY Non-Final OA UNIVERSITY OF SOUTHERN CALIFORNIA
18250065 MODULAR DENDRON MICELLES FOR COMBINATION IMMUNOTHERAPY Non-Final OA Wisconsin Alumni Research Foundation
17782436 FORMULATION COMPRISING STREPTOMYCES SPP. FOR USE IN SEED TREATMENT Final Rejection DANSTAR FERMENT AG
17837891 COMPOSITIONS AND METHODS FOR TREATMENT OF ABNORMAL CELL GROWTH Non-Final OA Pfizer Inc.
16297194 FORMULATIONS OF VILOXAZINE Final Rejection Supernus Pharmaceuticals, Inc.
17544987 FOAM IN WOUND TREATMENT Non-Final OA Mölnlycke Health Care AB
17601331 COSMETIC PREPARATION CONTAINING ULTRAVIOLET WAVELENGTH CONVERSION MATERIAL AND WATER-SOLUBLE THICKENING AGENT Final Rejection Shiseido Company, Ltd.
18613017 SOLID DISPERSION OF RIFAXIMIN Final Rejection Lupin Limited
18560137 IMMUNOGENIC COMPOSITION Non-Final OA GRIFFITH UNIVERSITY
18433424 Regulator for Highland Barley and Preparation Method and Application Thereof Non-Final OA Institute of Crop Science, Chinese Academy of Agricultural Sciences
18362383 TREATMENTS FOR UTERINE FIBROIDS Non-Final OA RESURGE THERAPEUTICS, INC.
17192155 METHOD OF MAKING SOLANACEAE FRUIT EXTRACTS Final Rejection Provexis Natural Products Limited
18532571 ANTIBACTERIAL COMPOSITION FOR GLASS COATING AND ANTIBACTERIAL GLASS Non-Final OA RIGMAH GLASS Co., Ltd.
18268997 FORMULATION COMPRISING ERBIUM BORATE FOR USE IN PREVENTION AND TREATMENT OF WOUND SCARS Non-Final OA YEDITEPE UNIVERSITESI
18220852 ENCAPSULATION OF PEROXIDES FOR SKIN APPLICATIONS Final Rejection Arkema Inc.
18494791 Biostimulant and method for stimulating plant growth Non-Final OA ELICIR
18286843 Poorly Soluble Chain-like Drug-entrapped Polymeric Micelle, and Preparation Method and Use Thereof Non-Final OA Hangzhou Hanjing Biotechnology Co., Ltd
18555277 POMACE LEACHATE HERBICIDE COMPOSITION AND METHODS Non-Final OA JACKSON FAMILY WINES, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month